Furthermore, the preponderance of oncogenic NOTCH1 mutations in T-ALL (40% to 70% of childhood and adult T-ALL) [120,121] has driven the search for effective anti-Notch1 therapeutics. Here, NOTCH1 is linked to acute lymphoblastic leukemia.